Skip to content

TIA: a feasibility study of telemedicine in addictions

Telemedicine in Addictions Randomised Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN36756455
Enrollment
60
Registered
2019-12-02
Start date
2019-09-24
Completion date
Unknown
Last updated
2023-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid dependence Mental and Behavioural Disorders

Interventions

Service users who accept to participate in the study will be randomly assigned to either Telemedicine appointments or face-to-face appointments (treatment as usual). Service users will have their next

Sponsors

Humber Teaching NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of opioid dependence 2. Prescribed opioid substitution treatment (OST) e.g. methadone or buprenorphine 3. Aged 18 years to 65 years 4. Willing and able to provide informed consent 5. Attending an outreach (spoke) clinic for keyworker appointments

Exclusion criteria

Exclusion criteria: 1. Service users who cannot read English AND would require the service of an interpreter to understand a brief oral description of the study 2. Service users who have already entered the trial

Design outcomes

Primary

MeasureTime frame
Attendance at appointments measured using electronic care records Feasibility outcomes: 1. Recruitment rate measured using a count of consent forms at follow-up (20 weeks) 2. Retention rate measured using a count of completed questionnaires at follow-up (20 weeks) 3. Acceptability of the study - views and experiences of service users and staff measured using a research interview at follow-up (20 weeks)

Secondary

MeasureTime frame
1. Patient satisfaction measured using the Patient Satisfaction Questionnaire (PSQ) and the Telemedicine Satisfaction Questionnaire (TSQ) (Telemedicine arm only) at the end of the first and second consultations 2. Travel distance measured using electronic care records 3. Addiction changes that occur during treatment measured using the Treatment Outcome Profile (TOP) and urine tests at baseline and at follow-up (20 weeks) 4. Patient and staff evaluation of the process measured using a process evaluation interview at follow-up (20 weeks) 5. Addictions prescriber satisfaction measured using a non-validated questionnaire at follow-up (20 weeks)

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026